WallStSmart
IOBT

IO Biotech Inc

NASDAQ: IOBT · HEALTHCARE · BIOTECHNOLOGY

$0.05
+0.00% today

Updated 2026-04-07

Market cap
$2.32M
P/E ratio
P/S ratio
EPS (TTM)
$-1.34
Dividend yield
52W range
$0 – $3
Volume
14.5M

IO Biotech Inc (IOBT) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item201920202021202220232024
Total assets$9.42M$5.65M$222.29M$151.81M$150.72M$67.70M
Cash & equivalents$7.85M$3.40M$211.53M$142.59M$143.19M$60.03M
Current assets$9.40M$5.63M$221.74M$148.22M$147.25M$64.95M
Total liabilities$10.89M$3.05M$10.36M$12.95M$17.56M$20.68M
Current liabilities$10.84M$3.05M$10.30M$10.68M$15.72M$19.49M
Long-term debt
Shareholder equity$-1.47M$2.60M$211.92M$138.85M$133.16M$47.02M
Retained earnings$-26.36M$-38.40M$-106.28M$-177.74M$-263.82M$-359.31M
Accounts receivable$1.23M$1.50M$2.09M$1.53M$1.13M$1.13M
Inventory$221000.00$359000.00$-2.09M$-1.53M
Goodwill

Frequently asked questions

How much free cash flow does IOBT generate?

IOBT produced $-82.39M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is IOBT's balance sheet healthy?

IOBT holds $60.03M in cash and equivalents against — in long-term debt, on $47.02M of shareholder equity. That debt is best read against the cash flow the business throws off each year.